Skip to content
    VNDA
    Earnings call· Jun 2026(Q2 FY26)

    Vanda Pharmaceuticals Q2 FY26 earnings call VNDA

    Aug 5, 2026 Source

    Executive summary

    Vanda Q2 FY26 — Strong FENAPT Growth and Pipeline Progress

    Vanda Pharmaceuticals reported strong Q2 FY26 performance, primarily driven by FENAPT's continued growth and the commercial launch of Nereus, alongside significant pipeline advancements including Bisanti's approval and Quimilza's upcoming PDUFA date. Despite increased operating expenses for pipeline development and commercialization efforts, the company anticipates expenses to moderate by year-end 2026 and into 2027, with current resources projected to fund operations through at least the end of 2027.

    Highlights

    5

    • FENAPT net product sales increased 23% to $36 million in Q2 FY26, driven by a 31% increase in total prescriptions (TRX) and a 32% increase in new-to-brand prescriptions (NBRX) year-over-year.

    • Bisanti received U.S. FDA approval for bipolar I disorder and schizophrenia in Q1 FY26 and is on track for launch in the second half of 2026.

    • Nereus commercially launched in the U.S. in May 2026 with a direct-to-consumer offering.

    • Quimilza's Biologic License Application (BLA) is under FDA review with a PDUFA date of December 12, 2026, and received orphan drug designations in Japan and a positive EMA opinion.

    • Vanda expects operating expenses to begin moderating by the end of 2026 and more substantially in 2027, with sufficient resources to fund operations through at least the end of 2027.

    Concerns

    5

    • Hetlios net product sales decreased 66% to $5.6 million in Q2 FY26, primarily due to generic competition and timing of shipments.

    • Vanda recorded a net loss of $62.5 million in Q2 FY26, compared to a net loss of $27.2 million in Q2 FY25.

    • Operating expenses increased by $23.2 million to $114.3 million in Q2 FY26, driven by higher R&D and SG&A for commercialization and pipeline programs.

    • Cash, cash equivalents, and marketable securities decreased by $93.8 million from December 31, 2025, to $170 million as of June 30, 2026.

    • Nereus net product sales were constrained by $12.6 million in Q2 FY26 due to uncertainties in patient demand and product returns related to elevated wholesaler inventory.

    Guidance & targets

    7
    CategoryTargetConfidence
    Full-year 2026 Total Revenue
    $240M-$290M
    high materiality
    High
    Full-year 2026 FNAPT and Basanti Net Product Sales
    $150M-$170M
    high materiality
    High
    Full-year 2026 Other Net Product Sales
    $80M-$90M
    medium materiality
    High
    Full-year 2026 Nereus Net Product Sales
    $10M-$30M
    medium materiality
    High
    Operating Expenses
    Begin decreasing by end of 2026 and more substantially throughout 2027
    high materiality
    High
    Cash Burn
    Greater than 2025 cash burn
    high materiality
    Medium
    Resources to Fund Operations
    Sufficient through at least the end of 2027
    high materiality
    High

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    FENAPT
    Net product sales for the first six months of 2026 were $65.5 million, a 24% increase compared to $52.8 million in the same period in 2025, attributable to increased volume, partially offset by decreased net price.
    TRX: up 31% YoYNBRX: up 32% YoYTRX: up 11% QoQNBRX: up 10% QoQTRX since bipolar I approval: up 62% vs Q2 FY24NBRX since bipolar I approval: up 300% vs Q2 FY24Weekly TRX: over 2,700 (11-year high in May 2026)Wholesaler inventory: slightly above 4 weeks on hand (consistent with Q1 FY26 and Q4 FY25, slightly above historic 3-4 week range)
    		$36.0M23%22%—
    HETLIOs
    Decrease due to generic competition and timing of shipments. $7 million in revenue for orders shipped on June 29, 2026, arrived on July 1, 2026, and will be recognized in Q3 FY26. Destocking by specialty pharmacy customers occurred in Q2 FY26. Despite generic competition for over three years, Hetlios remains the leading product from a market share perspective. Net product sales for the first six months of 2026 were $21.5 million, a 42% decrease compared to $37.1 million in the same period in 2025.
    		$5.6M-66%-65%—
    PONVORI
    Specialty distributor and specialty pharmacy inventory levels were in line with normal ranges. An amount of variable consideration related to net product sales, of which approximately $3 million was recognized for Q4 FY24, is subject to dispute. Net product sales for the first six months of 2026 were $14.1 million, an 11% increase compared to $12.7 million in the same period in 2025.
    		$7.9M12%27%—
    Nereus
    Commercially available in the U.S. in May 2026. Sold using both traditional wholesaler channel and direct-to-consumer via nereus.us website. Revenue recognized primarily related to units sold through the wholesaler channel. Personal promotion using existing sales force expected to commence later in 2026. Net product sales for the first six months of 2026 were $1.0 million.
    Initial stocking by wholesalers: $15.2MConstrained revenue: $12.6M (due to patient demand uncertainty and product returns from elevated inventory)
    		$1.0M———

    Operational metrics

    12
    Total Revenues
    $102.2Mvs $102.6M H1 FY25
    H1 FY26

    Essentially flat compared to the same period in 2025.

    Net Loss
    $111.1Mvs $56.7M H1 FY25
    H1 FY26

    Increased net loss compared to the same period in 2025.

    Income Tax Expense
    $0.3Mvs $15.6M benefit H1 FY25
    H1 FY26

    Compared to an income tax benefit in the prior year. A one-time non-cash income tax charge was recorded in Q4 FY25 to establish a valuation allowance against deferred tax assets.

    Operating Expenses
    $216.3Mvs $182.82M H1 FY25
    H1 FY26

    Primarily driven by higher SG&A expenses related to commercial products and higher R&D expenses for VQW765, FENAPT, and Basanti programs, partially offset by lower expenses on Quimilza.

    Total Revenues
    $50.5Mdown 4% vs Q2 FY25; down 2% vs Q1 FY26
    Q2 FY26

    Decreases primarily due to decreased Hetlios revenue, partially offset by FENAPT growth. Excludes approximately $7 million of Hetlios revenue for orders shipped on June 29 that arrived on July 1.

    Net Loss
    $62.5Mvs $27.2M Q2 FY25
    Q2 FY26

    Increased net loss compared to the second quarter of 2025.

    Income Tax Expense
    $0.1Mvs $7.7M benefit Q2 FY25
    Q2 FY26

    Compared to an income tax benefit in the prior year.

    Operating Expenses
    $114.3Mvs $91.1M Q2 FY25
    Q2 FY26

    Primarily driven by higher R&D expenses related to VQW and Nereus programs, and higher SG&A expenses for commercial products and upcoming launches.

    Cash, Cash Equivalents, and Marketable Securities
    $170Mdecrease of $93.8M vs Dec 31, 2025; decrease of $32.3M vs Mar 31, 2026
    As of June 30, 2026

    Decrease driven by net loss, timing of cash flows, and a one-time milestone payment to Eli Lilly.

    Eli Lilly Milestone Payment
    $10M
    Q1 FY26

    One-time milestone payment made for the approval of Nereus in the U.S.

    FENAPT Sales Force Size
    300
    H2 FY25

    Expanded in the second half of 2025 to significantly increase reach and frequency with prescribers.

    FENAPT Face-to-Face Calls
    >30%higher than Q2 FY25
    Q2 FY26

    Reflects increased commercial activity and reach of the expanded sales force.

    Industry KPIs

    1
    MetricValueDetails
    Therapeutic drug market shareLeading product

    Product announcements

    2
    ProductTypeDetails
    Nereuslaunch
    Bisantilaunch

    Risks & headwinds

    4
    Hetlios Generic CompetitionOngoing

    66% decrease in Q2 FY26 net product sales to $5.6M; 42% decrease in H1 FY26 net product sales to $21.5M

    Mitigation: Focus on market share leadership despite competition; managing inventory levels.

    Nereus Revenue ConstraintNear-term

    $12.6M of net product sales constrained in Q2 FY26

    Mitigation: Uncertainties of patient demand and product returns related to elevated wholesaler inventory; personal promotion expected to commence later in 2026.

    Increased Operating Expenses2025-2026

    $23.2M increase in Q2 FY26 OpEx to $114.3M; $34.1M increase in H1 FY26 OpEx to $216.3M

    Mitigation: Expectation for operating expenses to begin decreasing by end of 2026 and more substantially throughout 2027 as pipeline and launch activities conclude.

    Higher Cash BurnFY26

    2026 cash burn likely greater than 2025; cash balance decreased by $93.8M since Dec 31, 2025, to $170M as of June 30, 2026

    Mitigation: Anticipated future revenues and expected moderation of operating expenses to ensure sufficient resources through at least end of 2027.

    What to watch in Q3 FY26

    5

    Nereus Sales Trajectory

    Next quarter / H2 FY26
    Current$1.0M in Q2 FY26 (constrained by $12.6M)
    TargetImpact of personal promotion and improved patient acquisition/refill metrics

    Why it matters

    To assess the commercial momentum and potential to reach the full-year guidance range of $10M-$30M, especially as personal promotion begins.

    As far as metrics go for what folks should be looking for there, I think that as we continue to report going forward⏳, the sales engagement and the visits that we see with doctors and the receptivity to the product in the market is going to be important to seeing what trends we see as far as revenue goes.

    Q&A highlights

    5

    With three months of Nereus launch experience, where are the biggest drop-offs in the patient funnel, and what metrics should investors watch to judge if 2026 sales will be at the low or high end of the $10M-$30M range?

    Management stated it's very early in the launch phase. Personal promotion with the sales force will begin later in 2026. Key metrics for investors to watch include sales engagement, doctor receptivity, patient acquisition, refill rates, and pills-per-fill metrics, though current data is minimal.

    “As far as metrics go for what folks should be looking for there, I think that as we continue to report going forward, the sales engagement and the visits that we see with doctors and the receptivity to the product in the market is going to be important to seeing what trends we see as far as revenue goes.”

    asked by Raghuram Ram Silvaraj (H.G. Wainwright) · answered by Kevin Moran

    2 min read5 chapters

    Detailed Narrative

    01

    Commercial Strategy & Infrastructure

    Vanda is strategically investing in its commercial infrastructure, expanding its FENAPT sales force to approximately 300 representatives in the second half of 2025. This expansion led to a more than 30% increase in face-to-face calls in Q2 FY26 compared to Q2 FY25, significantly increasing reach and frequency with prescribers. This infrastructure supports FENAPT, Pomvori, and upcoming launches of Nereus and Basanti, with these commercial efforts expected to continue contributing to revenue growth.

    02

    Pipeline & Regulatory Progress

    The company is advancing multiple Phase 3 programs, with several top-line results expected in 2026 or early 2027, including Nereus for GLP-1 induced vomiting, VQW765 for social anxiety disorder, HETLIOs for delayed sleep phase disorder (DSPD), and Vysanti for major depressive disorder (MDD). Quimilza's BLA is under FDA review with a December 12, 2026 PDUFA date, and it has received orphan drug designations in Japan and a positive opinion from the EMA. Additionally, VCA894A received rare pediatric disease designation for CMT2S.

    03

    HETLIOs Legal Proceedings

    Vanda is progressing with an FDA formal hearing regarding HETLIOs for jet-lag disorder. This rare administrative hearing process, granted after a district circuit set aside the FDA's prior refusal, is advancing according to schedule. It is expected to culminate in a five-year hearing before an Administrative Law Judge in December 2026, with a favorable recommendation from the judge hoped for in early 2027.

    04

    Nereus Launch Dynamics

    Nereus commercially launched in the U.S. in May 2026 with a direct-to-consumer offering via nereus.us. Initial stocking by wholesalers amounted to $15.2 million, but $12.6 million of net product sales were constrained due to uncertainties in patient demand and product returns related to elevated inventory levels. Personal promotion by the existing sales force is expected to commence later in 2026 to support commercial activities.

    05

    Operating Expense Outlook

    Operating expenses significantly increased in 2025 and 2026 due to advancing multiple Phase 3 programs and preparing for commercial launches of Nereus, Basanti, and Imsidolimab, including manufacturing commercial supplies. As these activities conclude, operating expenses are expected to begin decreasing by the end of 2026 and more substantially throughout 2027, contributing to improved financial efficiency.

    AI-generated summary of the company’s earnings call. Not investment advice.